Specific oxylipins enhance vertebrate hematopoiesis via the receptor GPR132.

Autor:	Lahvic JL; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Ammerman M; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Li P; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Blair MC; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Stillman ER; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Fast EM; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138.; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138., Robertson AL; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Christodoulou C; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Perlin JR; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Yang S; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Chiang N; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115., Norris PC; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115., Daily ML; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Redfield SE; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Chan IT; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Chatrizeh M; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Chase ME; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Weis O; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Zhou Y; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115., Serhan CN; Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA 02115., Zon LI; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115; zon@enders.tch.harvard.edu.; Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115.; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138.; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138.; Howard Hughes Medical Institute, Boston Children's Hospital, Boston, MA 02115.
Jazyk:	angličtina
Zdroj:	Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2018 Sep 11; Vol. 115 (37), pp. 9252-9257. Date of Electronic Publication: 2018 Aug 23.
DOI:	10.1073/pnas.1806077115
Abstrakt:	Epoxyeicosatrienoic acids (EETs) are lipid-derived signaling molecules with cardioprotective and vasodilatory actions. We recently showed that 11,12-EET enhances hematopoietic induction and engraftment in mice and zebrafish. EETs are known to signal via G protein-coupled receptors, with evidence supporting the existence of a specific high-affinity receptor. Identification of a hematopoietic-specific EET receptor would enable genetic interrogation of EET signaling pathways, and perhaps clinical use of this molecule. We developed a bioinformatic approach to identify an EET receptor based on the expression of G protein-coupled receptors in cell lines with differential responses to EETs. We found 10 candidate EET receptors that are expressed in three EET-responsive cell lines, but not expressed in an EET-unresponsive line. Of these, only recombinant GPR132 showed EET-responsiveness in vitro, using a luminescence-based β-arrestin recruitment assay. Knockdown of zebrafish gpr132b prevented EET-induced hematopoiesis, and marrow from GPR132 knockout mice showed decreased long-term engraftment capability. In contrast to high-affinity EET receptors, GPR132 is reported to respond to additional hydroxy-fatty acids in vitro, and we found that these same hydroxy-fatty acids enhance hematopoiesis in the zebrafish. We conducted structure-activity relationship analyses using both cell culture and zebrafish assays on diverse medium-chain fatty acids. Certain oxygenated, unsaturated free fatty acids showed high activation of GPR132, whereas unoxygenated or saturated fatty acids had lower activity. Absence of the carbon-1 position carboxylic acid prevented activity, suggesting that this moiety is required for receptor activation. GPR132 responds to a select panel of oxygenated polyunsaturated fatty acids to enhance both embryonic and adult hematopoiesis. Competing Interests: The authors declare no conflict of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu